Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Curcumin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.97 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.97 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.97 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.97 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.97 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.97 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.97 |
| ▸ | VDR known ✓ | P11473 | 1/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.97 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.97 |
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.97 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.97 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.97 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.97 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.97 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.97 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.97 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Curcumin SCHEMBL15380842 | 1.00 | APP (0.97) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL29636029 | 1.00 | APP (0.97) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL6901740 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL2804734 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL8440 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL17629819 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL8336603 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL17629818 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL250984 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL29360171 | 0.98 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857379-B1 | METHOD FOR THE SYNTHESIS OF CURCUMIN | ASAC COMPANIA DE BIOTECNOLOGIA E INVESTIG SA (ES) | 2020-09-02 | — | — | EP | claimed |
| CN-108289476-A | Hydration of animals | 雀巢产品技术援助有限公司 | 2018-07-17 | — | — | CN | claimed |
| EP-2857379-A1 | METHOD FOR THE SYNTHESIS OF CURCUMIN | Asac Compañía De Biotecnología E Investigación SA (ES) | 2015-04-08 | — | — | EP | claimed |
| US-20210369667-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS, ECZEMA, BURNS, WOUNDS AND CERTAIN CANCERS | TPC-API LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2020205539-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS, ECZEMA, BURNS, WOUNDS AND CERTAIN CANCERS | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-2857379-B1 | METHOD FOR THE SYNTHESIS OF CURCUMIN | ASAC COMPANIA DE BIOTECNOLOGIA E INVESTIG SA (ES) | 2020-09-02 | — | — | EP | disclosed |
| EP-2857379-A1 | METHOD FOR THE SYNTHESIS OF CURCUMIN | Asac Compañía De Biotecnología E Investigación SA (ES) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857379-A1 | METHOD FOR THE SYNTHESIS OF CURCUMIN | Asac Compañía De Biotecnología E Investigación SA (ES) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013167770-A1 | METHOD FOR THE SYNTHESIS OF CURCUMIN | ASAC COMPAÑÍA DE BIOTECNOLOGÍA E INVESTIGACION SA (ES) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369667-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS, ECZEMA, BURNS, WOUNDS AND CERTAIN CANCERS | TP53, TYR, CUTA | HDAC3 3301/4885HDAC1 2210/4885HDAC2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.